Stock listing

NASDAQ:AVIR Atea Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Atea Pharmaceuticals, Inc.

Follow Atea Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:AVIR

$3.96 USD -0.03 (-0.8%)

Close on Nov 20, 2026

Past year +32.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.80 – $4.09 USDNov 20, 2026
Volume
416,457 sharesNov 20, 2026
Market cap
$317.6M USDAt the close on Nov 20, 2026 · price × 80.20M shares outstanding
52-week range
$2.93 – $6.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.38M USDMedian day 279,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Atea Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:AVIR · Home$3.96 USD-0.03 (-0.8%)416,457$3.88$4.09$3.80$3.99Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AVIR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.96-0.03-0.8%$3.88$4.09$3.80416,457
$3.99+0.03+0.8%$3.93$4.03$3.87342,249
$3.96-0.16-3.9%$4.11$4.18$3.85448,459
$4.12-0.18-4.2%$4.33$4.365$4.10310,527
$4.30+0.09+2.1%$4.25$4.35$4.10302,651
$4.21-0.01-0.2%$4.17$4.28$4.09243,885
$4.22+0.02+0.5%$4.22$4.34$4.04320,528
$4.20-0.21-4.8%$4.40$4.44$4.16301,493
$4.41+0.10+2.3%$4.35$4.475$4.315244,167
$4.31+0.09+2.1%$4.21$4.34$4.12199,472
$4.22-0.24-5.4%$4.48$4.49$4.19298,410
$4.46+0.29+7.0%$4.29$4.49$4.24268,893
$4.17+0.07+1.7%$4.14$4.33$4.105391,257
$4.10-0.01-0.2%$4.15$4.24$3.945330,293
$4.11-0.20-4.6%$4.30$4.32$4.07349,862
$4.31+0.04+0.9%$4.30$4.50$4.26280,900
$4.27+0.10+2.4%$4.15$4.27$4.14328,400
$4.17+0.01+0.2%$4.14$4.29$4.05245,200
$4.16+0.12+3.0%$4.04$4.24$3.94251,100
$4.04-0.01-0.2%$4.03$4.11$3.93245,400
$4.05-0.03-0.7%$4.08$4.17$4.02318,800
$4.08-0.385-8.6%$4.47$4.47$4.05465,200
$4.465+0.075+1.7%$4.34$4.58$4.315288,800
$4.39+0.07+1.6%$4.34$4.42$4.17390,000
$4.32-0.21-4.6%$4.54$4.55$4.30345,800
$4.53-0.10-2.2%$4.64$4.805$4.48319,400
$4.63-0.35-7.0%$4.92$4.92$4.60414,500
$4.98-0.05-1.0%$5.03$5.04$4.87303,200
$5.03-0.12-2.3%$5.13$5.20$5.03190,700
$5.15-0.005-0.1%$5.15$5.23$5.09158,000
$5.155+0.145+2.9%$4.98$5.23$4.91350,900
$5.01-0.06-1.2%$5.02$5.23$4.99264,800
$5.07-0.06-1.2%$5.16$5.19$4.98229,400
$5.130.000.0%$5.12$5.18$4.945293,600
$5.13+0.03+0.6%$5.16$5.215$5.05253,300
$5.10-0.11-2.1%$5.16$5.20$4.93408,700
$5.21+0.03+0.6%$5.20$5.29$5.14296,300
$5.18-0.02-0.4%$5.20$5.23$5.08298,300
$5.20+0.03+0.6%$5.15$5.30$5.10238,400
$5.170.000.0%$5.16$5.21$5.04280,700
$5.17-0.11-2.1%$5.28$5.305$5.14228,800
$5.28-0.36-6.4%$5.60$5.60$5.25232,300
$5.64+0.21+3.9%$5.46$5.655$5.38237,500
$5.43+0.10+1.9%$5.36$5.52$5.325440,100
$5.33+0.07+1.3%$5.21$5.37$5.17600,400
$5.26+0.11+2.1%$5.21$5.33$5.20279,400
$5.15-0.08-1.5%$5.23$5.33$5.15274,200
$5.23-0.09-1.7%$5.30$5.30$5.12224,300
$5.32+0.01+0.2%$5.31$5.455$5.25272,800
$5.31+0.13+2.5%$5.23$5.41$5.18489,500
$5.18-0.09-1.7%$5.22$5.30$5.17251,100
$5.27-0.41-7.2%$5.64$5.66$5.24430,800
$5.68-0.15-2.6%$5.80$5.85$5.635216,600
$5.83+0.01+0.2%$5.77$5.90$5.76199,100
$5.82+0.12+2.1%$5.70$5.84$5.63198,500
$5.70+0.21+3.8%$5.51$5.73$5.51289,900
$5.49+0.14+2.6%$5.31$5.51$5.31253,300
$5.35-0.01-0.2%$5.36$5.41$5.31198,400
$5.36-0.09-1.7%$5.48$5.51$5.29144,700
$5.45-0.06-1.1%$5.48$5.59$5.41102,900
$5.51+0.08+1.5%$5.43$5.59$5.30214,100
$5.43-0.08-1.5%$5.51$5.62$5.39198,064
$5.51+0.08+1.5%$5.385$5.53$5.25100,100
$5.43+0.07+1.3%$5.40$5.64$5.31209,900
$5.36-0.23-4.1%$5.52$5.545$5.35214,300
Ticker
NASDAQ:AVIR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Atea Pharmaceuticals, Inc. news

Atea Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 107 in all · newest Nov 9, 2026 · oldest 2020
Calls
19 calls with a replay · 19 with a transcript · latest Aug 12, 2026
Decks
12 decks · latest Aug 12, 2026

Where Atea Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AVIR · Home listing · This pageNASDAQUnited StatesUSD
BOATS:AVIRBOATSUnited StatesUSD

Valuation

Price/book 1.8× against a median of 2.5×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$126.6M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.8×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.86

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Atea Pharmaceuticals, Inc. · NASDAQ:AVIRUS$317.6MUS$126.6Mn/an/an/a1.8×n/a0.0×0.86
Lyell Immunopharma, Inc. · NASDAQ:LYELUS$339.3MUS$196.5Mn/a13,099×n/a1.8×n/a0.2×1.51
Avacta Group PLC · LSE:AVCTUS$337.8MUS$337.2Mn/a2,281×n/a68.5×n/a5.3×n/a
Inovio Pharmaceuticals, Inc. · NASDAQ:INOUS$329.7MUS$7.56Bn/a25,303×3.4×n/an/an/a0.70
Larimar Therapeutics, Inc. · NASDAQ:LRMRUS$328.6MUS$204.7Mn/an/an/a3.2×n/a0.1×1.48
CytoDyn Inc. · OTC:CYDYUS$326.4MUS$345.8Mn/an/an/an/an/an/a0.44
C4 Therapeutics, Inc. · NASDAQ:CCCCUS$325.7MUS$175.5Mn/a5.4×n/a1.4×−282.2%0.2×1.46
Laekna, Inc. · HKEX:2105US$322.8MUS$154.3Mn/a9.6×n/a1.8×−214.9%0.0×n/a
Foresee Pharmaceuticals Co., Ltd. · TPEX:6576US$319.8MUS$303.4M469×21.2×n/a8.3×4.8%0.3×n/a
GI Innovation, Inc. · KRX:358570US$315.9MUS$286.8Mn/an/an/a4.4×n/a0.0×n/a
MapLight Therapeutics, Inc. · NASDAQ:MPLTUS$313.9MUS$29.84Mn/an/an/a0.7×n/a0.0×1.28
Median of the othersUS$326.0MUS$245.7M469×1,151×3.4×2.5×−214.9%0.1×1.37

Forecasts

2 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
8.50 USD · Analysts' mean
EPS, year to Dec 2026
-1.99 · 2 analysts

Team and board

Officers

OfficerRole
Jean-Pierre SommadossiChairman & CEO, Atea Pharmaceuticals
Andrea CorcoranCFO & Executive VP, Legal
Shari NobleVP, Deputy General Counsel
Atea Pharmaceuticalswebsite at ir.ateapharma.com
Jonae BarnesSenior VP, Investor Relations & Corporate Communications
Jonae BarnesSVPInvestor Relations and Corporate
Adam DeZureSenior VP, Clinical Development
Adel MoussaEXECUTIVE VP, CHEMISTRY
Brian RoweVP, Business Development
Bruce BelangerSenior VP, Biostatistics
James MB EvansSENIOR VP, CMC Manufacturing
Jayanthi WolfExecutive VP, Regulatory Affairs
Keith PietropaoloExecutive VP, Clinical Sciences and Project Management
Laura IshakSenior VP, Clinical Operations
Marc Van HulleVP, Finance
Nancy AgrawalExecutive VP, Preclinical Development
Qi HuangSenior VP, Virology
Wayne FosterEXECUTIVE VP, Chief Accounting Officer
Xiao-Jian ZhouEXECUTIVE VP, EARLY STAGE DEVELOPMENT
Arantxa HorgaChief Medical Officer
Janet HammondCHIEF DEVELOPMENT OFFICER
John VavrickaCHIEF COMMERCIAL OFFICER
Polly A. MurphyChief Business Officer, Urogen Pharma

Board

DirectorRole
Jean-Pierre SommadossiChairman & CEO, Atea Pharmaceuticals
Barbara DuncanDirector
Howard BermanDirector
Polly A. MurphyChief Business Officer, Urogen Pharma

Events

Next results
Mar 4, 2027 (expected)

Calls

CallWhenStatus
Atea Pharmaceuticals (NASDAQ:AVIR) Q2 2026 Earnings CallWed, Aug 12, 2026 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q1 2026 Earnings CallTue, May 12, 2026 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q4 2025 Earnings CallThu, Mar 05, 2026 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q3 2025 Earnings CallWed, Nov 12, 2025 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q2 2025 Earnings CallThu, Aug 07, 2025 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q4 2024 Earnings CallThu, Mar 06, 2025 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q2 2024 Earnings CallWed, Aug 07, 2024 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q1 2024 Earnings CallTue, May 14, 2024 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q4 2023 Earnings CallWed, Feb 28, 2024 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q3 2023 Earnings CallWed, Nov 08, 2023 · 4:30 PM ETReplay
All 19 calls
CallWhenStatus
Atea Pharmaceuticals (NASDAQ:AVIR) Q2 2023 Earnings CallTue, Aug 08, 2023 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q1 2023 Earnings CallMon, May 08, 2023 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q4 2022 Earnings CallTue, Feb 28, 2023 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q3 2022 Earnings CallMon, Nov 07, 2022 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q2 2022 Earnings CallMon, Aug 08, 2022 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q4 2021 Earnings CallMon, Feb 28, 2022 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q3 2021 Earnings CallThu, Nov 11, 2021 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q2 2021 Earnings CallThu, Aug 12, 2021 · 4:30 PM ETReplay
Atea Pharmaceuticals (NASDAQ:AVIR) Q1 2021 Earnings CallThu, May 13, 2021 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 9, 2026 · After close−4.8%
Q2 2026Aug 12, 2026 · After close+0.2%
Q1 2026May 13, 2026−22.4%
Q4 2025Mar 5, 2026 · After close+11.1%
Q3 2025Nov 12, 2025 · After close−12.6%
Q2 2025Aug 7, 2025 · After close−2.3%
Q1 2025May 12, 2025 · After close−11.2%
Q4 2024Feb 26, 2025 · After close−3.2%
Q3 2024Nov 7, 2024 · After close+1.7%
Q2 2024Aug 7, 2024 · After close+7.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close−6.3%
Q4 2023Feb 28, 2024 · After close−1.4%
Q3 2023Nov 8, 2023 · After close−9.1%
Q2 2023Aug 8, 2023 · After close+3.8%
Q1 2023May 8, 2023 · After close−2.6%
Q4 2022Feb 28, 2023 · After close−8.2%
Q3 2022Nov 7, 2022 · After close−9.9%
Q2 2022Aug 8, 2022 · After close−1.3%
Q1 2022May 10, 2022 · Before open+9.9%
Q4 2021Feb 28, 2022 · After close+1.9%

Open Events

Decks

DeckKindSlidesDate
Q2 2026 Earnings PresentationEarnings31 slidesAug 12, 2026
Q1 2026 Earnings PresentationEarnings29 slidesMay 12, 2026
Q4 2025 Earnings PresentationEarnings28 slidesMar 5, 2026
44th Annual J.P. Morgan Healthcare Conference (January 2026)Conference25 slidesJan 15, 2026
Q3 2025 Earnings PresentationEarnings27 slidesNov 12, 2025
Q2 2025 Earnings PresentationEarnings26 slidesAug 7, 2025
FY2024 Earnings PresentationEarnings23 slidesMar 6, 2025
43rd Annual J.P. Morgan Healthcare Conference (January 2025)Conference22 slidesJanuary 2025
Q3 2024 Earnings PresentationEarnings18 slidesNov 7, 2024
Q2 2024 Earnings PresentationEarnings30 slidesAug 7, 2024
All 12 decks
DeckKindSlidesDate
JP Morgan Healthcare Conference 2022Conference28 slidesJan 10, 2022
Q1 2021 Earnings PresentationEarnings17 slidesMay 13, 2021

Open Decks

IPO

Priced at US$24.00 a share on Oct 29, 2020.

Price
US$24.00 a share
Shares offered
12,500,000 shares of common stock
Offering size
US$300 million
Underwriters' option
Up to 1,875,000 more shares
Underwriters
J.P. Morgan, Morgan Stanley, Evercore ISI, William Blair · In the order on the cover
Shares delivered
On or about Nov 3, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceJun 19, 2020
Filed publiclyOct 9, 2020
Amended twiceNewest Oct 26, 2020
Shares registered with an exchangeOct 26, 2020
Declared effective by the SECOct 29, 2020
Final prospectus, with the priceOct 30, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Oct 30, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue000192.2M351.4M48.6M00
Cost of revenue416.0K83.4M70.1M260.0K29.0K38.0M17.0K17.0K
Gross profit-416.0K-83.4M-70.1M-260.0K351.4M10.6M-17.0K-17.0K
Research and development148.0M144.1M114.2M81.9M167.2M38.0M10.2M6.67M
Selling, general and administrative32.9M48.8M49.9M48.7M45.8M21.6M4.44M2.80M
Operating income-180.9M-192.9M-164.2M-130.7M138.4M-11.0M-14.6M-9.48M
Depreciation and amortization416.0K416.0K416.0K260.0K29.0K19.0K17.0K17.0K
EBITDA-180.5M-192.5M-163.7M-130.4M138.4M-11.0M-14.6M-9.46M
Interest expense11.2M242.0K83.0K00
Income before tax-164.5M-167.5M-134.9M-119.5M138.6M-10.9M-14.0M-9.06M
Income tax-6.16M925.0K1.02M-3.59M17.4M-83.0K-574.0K413.0K
Net income-158.3M-168.4M-136.0M-115.9M121.2M-10.9M-14.0M-9.06M
Earnings per share, basic-1.94-2.00-1.63-1.391.46-0.51-1.39-0.90
Earnings per share, diluted-1.94-2.00-1.63-1.391.37-0.51-1.39-0.90

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents95.7M64.7M143.8M188.5M764.4M850.1M21.7M34.5M
Short-term investments206.1M390.0M434.3M458.2M0
Receivables5.82M
Current assets311.0M462.4M590.5M660.9M772.4M863.5M21.9M34.7M
Property, plant and equipment457.0K873.0K1.29M1.71M23.0K48.0K41.0K56.0K
Total assets315.2M464.7M595.0M666.7M772.9M863.6M22.1M34.9M
Accounts payable12.9M4.46M4.25M2.55M4.53M60.0K548.0K391.0K
Current liabilities39.8M18.6M32.4M18.5M56.9M315.8M2.44M1.76M
Total debt843.0K1.64M2.40M3.12M197.0K
Total liabilities39.8M25.8M39.8M26.1M62.8M315.8M2.53M71.0M
Shareholders' equity275.4M438.9M555.2M640.6M710.1M547.8M-49.6M-36.2M
Shares outstanding78.1M84.5M83.4M83.3M83.1M82.4M10.1M83.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-132.0M-135.5M-85.4M-121.0M-87.0M296.7M-12.8M-7.91M
Capital spending000-1.94M-4.00K-26.0K-2.00K-12.0K
Free cash flow-132.0M-135.5M-85.4M-122.9M-87.0M296.7M-12.8M-7.92M
Cash from investing188.8M56.1M40.3M-455.4M-4.00K-26.0K-2.00K-12.0K
Cash from financing-25.7M267.0K257.0K370.0K1.47M531.7M-15.0K27.5M
Share buybacks-25.5M01.47M531.7M
Change in cash31.0M-79.1M-44.8M-576.0M-85.5M828.5M-12.8M19.6M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 19, 2026Insider tradeSEC
144 · Notice of proposed saleNov 19, 2026Other filingsSEC
144 · Notice of proposed saleNov 19, 2026Other filingsSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
144 · Notice of proposed saleNov 18, 2026Other filingsSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
8-K · Current reportNov 9, 2026Material contractSEC
SCHEDULE 13G · Big-stake noticeOct 6, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
8-K · Current reportJun 22, 2026Meeting outcomeSEC
4/A · Change in ownership, amendedMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 27, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 27, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 9, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
8-K · Current reportJan 8, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 5, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
S-8 · Registration statement for employee plansAug 7, 2025Offer documentSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 24, 2025Insider tradeSEC
8-K · Current reportJun 20, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 23, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 17, 2025Big-stake noticeSEC
8-K · Current reportApr 17, 2025ResultsSEC
DEFA14A · Additional proxy materialApr 3, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialApr 1, 2025Meeting noticeSEC
8-K · Current reportApr 1, 2025Current reportSEC
DEFA14A · Additional proxy materialMar 26, 2025Meeting noticeSEC
DFAN14AMar 26, 2025Other filingsSEC
DEFA14A · Additional proxy materialMar 24, 2025Meeting noticeSEC
8-K · Current reportMar 24, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 21, 2025Big-stake noticeSEC
10-K · Annual reportMar 6, 2025Annual reportSEC
8-K · Current reportMar 6, 2025ResultsSEC
SCHEDULE 13D · Big-stake noticeMar 4, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 24, 2025Insider tradeSEC
8-K · Current reportFeb 24, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4/A · Change in ownership, amendedJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025ResultsSEC
SCHEDULE 13D · Big-stake noticeDec 16, 2024Big-stake noticeSEC
4 · Change in ownershipDec 12, 2024Insider tradeSEC
144 · Notice of proposed saleDec 10, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveNov 20, 2024Other filingsSEC
CORRESP · Letter to the SECNov 15, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 15, 2024Big-stake noticeSEC
UPLOAD · Letter from the SECNov 14, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
S-3 · Registration statementNov 7, 2024Offer documentSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
4 · Change in ownershipSep 19, 2024Insider tradeSEC
144 · Notice of proposed saleSep 19, 2024Other filingsSEC
144 · Notice of proposed saleSep 18, 2024Other filingsSEC
144 · Notice of proposed saleSep 17, 2024Other filingsSEC
10-Q · Quarterly reportAug 7, 2024Quarterly reportSEC
8-K · Current reportAug 7, 2024ResultsSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
8-K · Current reportJun 21, 2024Meeting outcomeSEC
144 · Notice of proposed saleJun 20, 2024Other filingsSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
144 · Notice of proposed saleJun 5, 2024Other filingsSEC
DEFA14A · Additional proxy materialJun 4, 2024Meeting noticeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
10-K · Annual reportFeb 28, 2024Annual reportSEC
8-K · Current reportFeb 28, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 15, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 15, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 7, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
144 · Notice of proposed saleFeb 1, 2024Other filingsSEC
144 · Notice of proposed saleFeb 1, 2024Other filingsSEC
144 · Notice of proposed saleFeb 1, 2024Other filingsSEC
144 · Notice of proposed saleFeb 1, 2024Other filingsSEC
144 · Notice of proposed saleFeb 1, 2024Other filingsSEC
144 · Notice of proposed saleFeb 1, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedJan 24, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedNov 28, 2023Big-stake noticeSEC
10-Q · Quarterly reportNov 8, 2023Quarterly reportSEC
8-K · Current reportNov 8, 2023ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 7, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeOct 2, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedSep 11, 2023Big-stake noticeSEC
10-Q · Quarterly reportAug 8, 2023Quarterly reportSEC
8-K · Current reportAug 8, 2023ResultsSEC
8-K · Current reportJun 21, 2023Meeting outcomeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
DEFA14A · Additional proxy materialJun 12, 2023Meeting noticeSEC
DEFA14A · Additional proxy materialMay 25, 2023Meeting noticeSEC
SC 13D · Big-stake noticeMay 22, 2023Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2023Quarterly reportSEC
8-K · Current reportMay 8, 2023ResultsSEC
ARS · Annual report to shareholdersApr 28, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
10-K · Annual reportFeb 28, 2023Annual reportSEC
8-K · Current reportFeb 28, 2023ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2023Big-stake noticeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
4 · Change in ownershipFeb 2, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 24, 2023Big-stake noticeSEC
4 · Change in ownershipNov 15, 2022Insider tradeSEC
10-Q · Quarterly reportNov 7, 2022Quarterly reportSEC
8-K · Current reportNov 7, 2022ResultsSEC
10-Q · Quarterly reportAug 8, 2022Quarterly reportSEC
8-K · Current reportAug 8, 2022ResultsSEC
4 · Change in ownershipJun 21, 2022Insider tradeSEC
4 · Change in ownershipJun 21, 2022Insider tradeSEC
4 · Change in ownershipJun 21, 2022Insider tradeSEC
4 · Change in ownershipJun 21, 2022Insider tradeSEC
4 · Change in ownershipJun 21, 2022Insider tradeSEC
4 · Change in ownershipJun 21, 2022Insider tradeSEC
8-K · Current reportJun 21, 2022Meeting outcomeSEC

This page holds 200 of 326 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Atea Pharmaceuticals, Inc.’s releases · as of Aug 10, 2026

Common shares
80,204,699
Fully diluted
80,204,699

Fully diluted

LineSharesAs of
Common shares80,204,699Aug 10, 2026

Share count over time

CountShares
Aug 10, 202680,204,699

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Fidelity12M15.0%US$62.7MSep 30, 2026
BlackRock9.06M11.3%US$47.2MSep 30, 2026
BML Capital Management, LLC6.75M8.4%US$35.2MSep 30, 2026
Tang Capital Management LLC4.81M6.0%US$25.1MSep 30, 2026
Vanguard4.04M5.0%US$21.1MSep 30, 2026
Acadian Asset Management LLC2.34M2.9%US$12.2MSep 30, 2026
Bain Capital Life Sciences Investors, LLC2.08M2.6%US$10.8MSep 30, 2026
Geode Capital1.91M2.4%US$9.96MSep 30, 2026
State Street1.63M2.0%US$8.48MSep 30, 2026
Two Sigma1.3M1.6%US$6.79MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Dimensional1.3M1.6%US$6.77MSep 30, 2026
Renaissance Technologies1.09M1.4%US$5.69MSep 30, 2026
JPMorgan925K1.2%US$4.79MSep 30, 2026
Northern Trust716K0.89%US$3.73MSep 30, 2026
Schwab638K0.79%US$3.32MSep 30, 2026
Morgan Stanley556K0.69%US$2.9MSep 30, 2026
AQR Capital Management LLC494K0.62%US$2.57MSep 30, 2026
Goldman Sachs478K0.60%US$2.49MSep 30, 2026
CM Management, LLC450K0.56%US$2.34MSep 30, 2026
Rock Springs Capital Management LP434K0.54%US$2.26MSep 30, 2026
D. E. Shaw & Co., Inc.353K0.44%US$1.84MSep 30, 2026
Banque Pictet & Cie SA345K0.43%US$1.8MSep 30, 2026
Arrowstreet Capital, Limited Partnership323K0.40%US$1.68MSep 30, 2026
Susquehanna303K0.38%US$1.58MSep 30, 2026
Rosalind Advisors, Inc.280K0.35%US$1.46MSep 30, 2026
Invesco254K0.32%US$1.33MSep 30, 2026
Quantinno Capital Management LP252K0.31%US$1.31MSep 30, 2026
Nuveen248K0.31%US$1.29MSep 30, 2026
Wellington247K0.31%US$1.28MSep 30, 2026
HSBC241K0.30%US$1.26MSep 30, 2026
BNY197K0.25%US$1.02MSep 30, 2026
Barclays175K0.22%US$914KSep 30, 2026
Auour Investments LLC172K0.21%US$896KSep 30, 2026
Strs Ohio171K0.21%US$891KSep 30, 2026
American Century170K0.21%US$887KSep 30, 2026
Millennium160K0.20%US$833KSep 30, 2026
UBS157K0.20%US$819KSep 30, 2026
Bridgeway Capital Management, LLC129K0.16%US$674KSep 30, 2026
AllianceBernstein118K0.15%US$613KSep 30, 2026
State Of Wisconsin Investment Board117K0.15%US$611KSep 30, 2026
T. Rowe Price116K0.14%US$604KSep 30, 2026
Bank of America109K0.14%US$567KSep 30, 2026
Empowered Funds, LLC91,2560.11%US$475KSep 30, 2026
Rhumbline Advisers88,0420.11%US$459KSep 30, 2026
Aldebaran Capital, LLC86,0680.11%US$448KSep 30, 2026
Nomura70,0000.09%US$365KSep 30, 2026
DWS61,5930.08%US$321KSep 30, 2026
Russell Investments Group, Ltd.55,3580.07%US$288KSep 30, 2026
Trexquant Investment LP54,9080.07%US$286KSep 30, 2026
Creative Planning50,8760.06%US$265KSep 30, 2026

This page holds 50 of 122 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Fidelity Growth Company Fund3.1M3.9%US$14.5MMay 31, 2026
Vanguard Total Stock Market Index Fund2.03M2.5%US$9.45MJun 30, 2026
iShares Russell 2000 ETF1.84M2.3%US$8.53MJun 30, 2026
Fidelity Growth Company K6 Fund1.22M1.5%US$5.69MMay 31, 2026
Vanguard Extended Market Index Fund865K1.1%US$4.02MJun 30, 2026
Fidelity Small Cap Index Fund771K0.96%US$3.63MJul 31, 2026
Fidelity Series Growth Company Fund734K0.92%US$3.43MMay 31, 2026
iShares Russell 2000 Value ETF669K0.83%US$3.11MJun 30, 2026
BlackRock Advantage Small Cap Core Fund613K0.76%US$2.86MMay 29, 2026
iShares Biotechnology ETF438K0.55%US$2.04MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Russell 2000 Index Fund359K0.45%US$1.68MMay 31, 2026
U.S. Small Cap Portfolio350K0.44%US$1.64MJul 31, 2026
Schwab U.S. Small-Cap ETF346K0.43%US$1.62MMay 31, 2026
Fidelity Extended Market Index Fund314K0.39%US$1.47MMay 31, 2026
Select Biotechnology Portfolio288K0.36%US$1.34MMay 31, 2026
Dimensional U.S. Small Cap ETF264K0.33%US$1.24MJul 31, 2026
JPMorgan U.S. Small Company Fund244K0.30%US$1.13MJun 30, 2026
iShares Micro-Cap ETF238K0.30%US$1.11MJun 30, 2026
U.S. Micro Cap Portfolio235K0.29%US$1.1MJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF180K0.22%US$838KJun 30, 2026
Schwab Small-Cap Index Fund172K0.21%US$810KJul 31, 2026
Vanguard Health Care Index Fund154K0.19%US$718KMay 31, 2026
Avantis U.S. Small Cap Equity ETF152K0.19%US$709KMay 31, 2026
Nuveen Equity Index Fund149K0.19%US$699KJul 31, 2026
BlackRock Advantage Small Cap Growth Fund143K0.18%US$664KJun 30, 2026
Fidelity Total Market Index Fund138K0.17%US$646KMay 31, 2026
Master Small Cap Index Series132K0.16%US$614KJun 30, 2026
JPMorgan Small Cap Value Fund126K0.16%US$585KJun 30, 2026
Strategic Advisers U.S. Total Stock Fund111K0.14%US$517KMay 31, 2026
Fidelity Series Total Market Index Fund108K0.13%US$503KMay 31, 2026
Small Cap Value Fund104K0.13%US$485KJun 30, 2026
Fidelity Small Cap Value Index Fund98,9390.12%US$460KJun 30, 2026
Fidelity Enhanced Small Cap Core ETF94,3510.12%US$439KJun 30, 2026
Ultra-Small Company Market Fund92,8000.12%US$432KJun 30, 2026
Nuveen Small Cap Blend Index Fund89,8880.11%US$422KJul 31, 2026
ALPS Medical Breakthroughs ETF82,1250.10%US$384KMay 31, 2026
U.S. Core Equity 1 Portfolio81,3000.10%US$382KJul 31, 2026
EQ/2000 Managed Volatility Portfolio70,2800.09%US$327KJun 30, 2026
Nomura Healthcare Fund70,0000.09%US$326KJun 30, 2026
Fidelity Nasdaq Composite Index ETF69,6180.09%US$325KMay 31, 2026
EQ/Small Company Index Portfolio65,9900.08%US$307KJun 30, 2026
Dimensional U.S. Core Equity 2 ETF58,1550.07%US$273KJul 31, 2026
Invesco BuyBack AchieversTM ETF57,4120.07%US$270KJul 31, 2026
T. Rowe Price Extended Equity Market Index Fund56,8000.07%US$264KJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF54,4980.07%US$256KJul 31, 2026
LVIP JPMorgan Small Cap Core Fund54,3470.07%US$253KJun 30, 2026
Vanguard Russell 2000 Value Index Fund54,0470.07%US$252KMay 31, 2026
Fidelity Nasdaq Composite Index Fund52,5330.07%US$245KMay 31, 2026
Diversified Equity Alpha Master Portfolio51,4590.06%US$239KJun 30, 2026
LVIP State Street Small-Cap Index Fund48,0000.06%US$223KJun 30, 2026

This page holds 50 of 148 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Murphy Polly A.
Director
Buy6,100USD 4.17US$25,437May 18, 2026

Big stakes

StakeStakeSharesDateFiling
FMR LLC15.00%12MMar 31, 2026Schedule 13G
Jean-Pierre Sommadossi11.00%9.08MSep 30, 2026Schedule 13G
Leonard Braden Michael9.90%7.81MDec 31, 2025Schedule 13G
BlackRock, Inc.7.10%6.08MMar 31, 2025Schedule 13G
Tang Capital Management LLC6.00%4.81MOct 6, 2026Schedule 13G
Radoff Bradley Louis4.00%3.38MApr 16, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Franklin Berger
Other companies: Retension Pharmaceuticals, Inc. (Director · Since at least Oct 13, 2026); ESSA Pharma Inc (Director · Since at least Oct 1, 2020); Kezar Life Sciences, Inc. (Director · Since at least Jun 25, 2019); Rain Oncology Inc (Director · Apr 22, 2021 – Jan 26, 2024 · Past); Kineta Inc. (Director · Jun 27, 2019 – Jun 29, 2020 · Past); Atreca Inc (Director · Jun 19, 2019 – Jun 13, 2023 · Past); Five Prime Therapeutics Inc (Director · Jun 10, 2019 – Apr 16, 2021 · Past); Tocagen Inc (Director · May 29, 2019 – Oct 4, 2019 · Past); Immune Design Corp (Director · Apr 2, 2019 – Apr 2, 2019 · Past)
Director · Since at least Oct 29, 2020
Andrew A F Hack
Other companies: Mersana Therapeutics Inc (Director · Since at least Jun 27, 2017); Nuvalent, Inc. (Director · Jul 28, 2021 – Dec 11, 2024 · Past); BCLS Acquisition Corp (Chief Financial Officer, Director · Oct 21, 2020 – Oct 26, 2020 · Past); Dynavax Technologies Corporation (Director · Aug 12, 2019 – Aug 8, 2023 · Past); Allena Pharmaceuticals Inc (Director · Jun 8, 2018 – Nov 17, 2020 · Past); Editas Medicine, Inc. (Chief Financial Officer · Feb 2, 2016 – Feb 4, 2019 · Past)
Director · Oct 29, 2020 – Nov 3, 2020 · Past
Arthur Kirsch
Other companies: Evommune, Inc. (Audit · Since at least Nov 5, 2025); Liquidia Corporation (Board Member · Since at least Mar 24, 2021); Kadmon Holdings Inc (Director · May 15, 2019 – Nov 9, 2021 · Past); Aralez Pharmaceuticals Inc (Director · May 12, 2016 – Dec 8, 2017 · Past)
Director · Since at least Feb 20, 2025
Barbara Duncan
Other companies: Halozyme Therapeutics, Inc. (Director · Since at least Apr 25, 2024); Ovid Therapeutics Inc. (Director · Since at least Feb 22, 2024); Fusion Pharmaceuticals Inc (Director · Jun 4, 2024 – Jun 4, 2024 · Past)
Director · Since at least Jun 16, 2024
Jean-Pierre Sommadossi
Other companies: ABG Acquisition I Corp (Director · Feb 16, 2021 – Mar 1, 2023 · Past); Kezar Life Sciences, Inc. (Director · Jun 20, 2018 – Jun 28, 2021 · Past); Idenix Pharmaceuticals Inc (President, CEO, Chairman, Director · Dec 31, 2005 – Feb 10, 2010 · Past)
Chairman & CEO, Atea Pharmaceuticals · Since at least Oct 29, 2020
Bruce Polsky
Other companies: Cogentix Medical Inc (Director · Jul 26, 2012 – Aug 26, 2013 · Past)
Director · Since at least Oct 29, 2020
Howard Berman
Other companies: Coya Therapeutics, Inc. (Executive Chairman, Director · Since at least Dec 28, 2022)
Director · Since at least Apr 17, 2025
Polly A. Murphy
Other companies: Celcuity Inc. (Director · Since at least Jun 24, 2024)
Director · Since at least Mar 26, 2025
Wayne Foster
Other companies: Mersana Therapeutics Inc (Vice President of Finance · Jun 27, 2017 – Jan 23, 2019 · Past)
EXECUTIVE VP, Chief Accounting Officer · Since at least Oct 29, 2020
Adam DeZureSenior VP, Clinical Development · Since at least Nov 5, 2026
All 32 people
PersonSeat
Adel MoussaEXECUTIVE VP, CHEMISTRY · Since at least Nov 5, 2026
Andrea CorcoranCFO & Executive VP, Legal · Since at least Oct 29, 2020
Arantxa HorgaChief Medical Officer · Since at least Mar 26, 2025
Atea Pharmaceuticalswebsite at ir.ateapharma.com · Since at least Aug 5, 2026
Brian RoweVP, Business Development · Since at least Nov 5, 2026
Bruce BelangerSenior VP, Biostatistics · Since at least Nov 5, 2026
Bruno LucidiDirector · Since at least Oct 29, 2020
James MB EvansSENIOR VP, CMC Manufacturing · Since at least Nov 5, 2026
Janet HammondCHIEF DEVELOPMENT OFFICER · Since at least Oct 29, 2020
Jayanthi WolfExecutive VP, Regulatory Affairs · Since at least Nov 5, 2026
Jerome M AdamsDirector · Since at least Jun 20, 2025
John VavrickaChief Commercial Officer · Since at least Oct 29, 2020
Jonae BarnesSenior VP, Investor Relations & Corporate Communications · Since at least Nov 2, 2026
Jonae BarnesSVPInvestor Relations and Corporate · Since at least Jul 28, 2026
Keith PietropaoloExecutive VP, Clinical Sciences and Project Management · Since at least Nov 5, 2026
Laura IshakSenior VP, Clinical Operations · Since at least Nov 5, 2026
Marc Van HulleVP, Finance · Since at least Nov 5, 2026
Maria Arantxa HorgaChief Medical Officer · Since at least Jan 31, 2023
Nancy AgrawalExecutive VP, Preclinical Development · Since at least Nov 5, 2026
Qi HuangSenior VP, Virology · Since at least May 13, 2026
Shari NobleVP, Deputy General Counsel · Since at least Nov 5, 2026
Xiao-Jian ZhouEXECUTIVE VP, EARLY STAGE DEVELOPMENT · Since at least May 13, 2026

Open People

Log in to ask 6ix AI your own questions about Atea Pharmaceuticals, Inc.